Core Insights - Creative Medical Technology Holdings, Inc. has successfully completed an independent interim safety review for its ADAPT clinical trial evaluating CELZ-201, a novel therapeutic product for chronic lower back pain [1][2][3] - The Data Safety Monitoring Board (DSMB) concluded that the trial may proceed, highlighting the safety profile of CELZ-201 and supporting its advancement [2][3] - The ADAPT trial is a double-blind, randomized, placebo-controlled, dose-escalation study designed to assess the safety, tolerability, and efficacy of CELZ-201 [3][4] Company Overview - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on regenerative medicine therapies derived from adult stem cells [5] - The company aims to develop targeted cellular therapies to address unmet medical needs, particularly in degenerative diseases [4][5] - CELZ-201 represents the company's commitment to delivering transformative treatments for patients suffering from chronic conditions [4][5]
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment